Generalized myasthenia gravis: Clinical trials to watch.

Generalized myasthenia gravis is undergoing a highly dynamic phase of therapeutic development, with ongoing trials increasingly targeting upstream immune mechanisms. This Trial Watch highlights six studies evaluating B cell survival modulation, lymphocyte-directed immune reconstitution, BCMA- and CD19-directed CAR-T cell therapy, T cell engagement, and response-guided combination therapy, and considers their implications for future treatment strategies.